During the past decade, the number of malaria cases reported in the Americas dropped more than 50%. Today, malaria transmission has stopped in many areas in our countries (though we cannot talk about its elimination yet), but continues in others, affecting populations living in what we may call special circumstances (such as Brazilian nut collectors, gold miners in the Amazon forest, Amazon native communities, and distant communities). In them, conventional strategies for malaria prevention and control do not work or cannot be implemented. To the Amazon Malaria Initiative, this represents one of our main challenges for the coming years if we aim to decrease the risk of malaria re-emergence.
See the photo.
The malaria parasite can ensure it keeps a host body all to itself by preventing further malarial infections, according to international researchers.
The parasite initially reproduces in the liver and moves into the blood.
A study on mice, published in Nature Medicine, showed the parasite can trigger iron deficiency in the liver and therefore prevent more infections.
Read more.In the first study of its type in the malaria field, Seattle BioMed has been awarded an $8.9 million grant from the Bill & Melinda Gates Foundation to identify biomarkers that will allow malaria vaccine design based on robust predictors of protective immunity. Ruobing Wang, M.D., Ph.D., will lead the study – Seattle BioMed's first to include the integration of its recently announced systems biology approach to infectious disease research – with a team that includes Seattle BioMed's Stefan Kappe, Ph.D., and Alan Aderem, Ph.D., along with Patrick Duffy, M.D., of the National Institutes of Health, Jonathan Derry, Ph.D., of Sage Bionetworks, and Xiaowu Liang, Ph.D., of Antigen Discovery Inc. (ADi).
You are viewing
ami_lm's journal